HRSA Unexpectedly Changes Policy on 340B Eligibility for Newly Established HOPD Sites
HRSA has purportedly reversed its stance on allowing newly established HOPDs, not yet on hospitals’ Medicare Cost Reports, to [...]
U.S. Court of Appeals Rules in Favor of Drug Manufacturers
On January 31st, 2023, the U.S. Court of Appeals for the Third Circuit found in favor of three drug [...]
340B ADR Proposed Rule – 2022
340B ADR Proposed Rule - 2022 On November 29, 2022, The Department of Health and Human Services (HHS) [...]
CMS Finalizes Rule to Reinstate Full 340B Drug Reimbursement
CMS FINALIZES RULE TO REINSTATE FULL 340B DRUG REIMBURSEMENT Yesterday, the Centers for Medicare & Medicaid Services (“CMS”) released [...]
District Court Vacates HHS’s 340B Reimbursement Cuts for the Remainder of 2022
District Court Vacates HHS’s 340B Reimbursement Rate Cuts for the Remainder of 2022 and Demands Restoration of Default Reimbursement [...]
Supreme Court Rules HHS’s 340B Reimbursement Rates Unlawful
Supreme Court Rules that HHS’s Reimbursement Rates for 340B Covered Entities in 2018 and 2019 are Unlawful – Covered [...]
340B Medication Management
Across the country, hospitals and health systems are struggling to deal with the immense cost and corresponding loss of [...]
Drug Manufacturers May Take Harmful Action: 340B Hospitals
Your 340B savings reduce margins for Big Pharma. Who needs the money more? Five major drug manufacturers have recently [...]
HRSA Issues Guidance: 340B Eligibility
HRSA Issues New Guidance: New Hospital Locations Immediately 340B- Eligible HRSA has issued new, permanent guidance for when [...]
Expanded 340B Eligibility: Act Now
Immediate 340B Eligibility Possible for New Facilities as part of COVID-19 Response The Health Resources and Services Administration [...]